| |
|
|
| 大津 敦 |
独立行政法人国立がん研究センター東病院
臨床開発センター長 |
| 腫瘍内科 |
| 1) Ohtsu A, Shah M, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-Line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III Study. J Clin Oncol, 29(30):3968-3976, 2011
|
| 2) Bang YJ, Van Cutsem E, Ohtsu A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010 |
| 3) Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 21: 54-59, 2003 |
|
|
| 北島 政樹 |
国際医療福祉大学 学長 |
| 消化器外科 |
| Masaki Kitajima, Yuko Kitagawa: Surgical Treatment of Esophageal Cancer- The Advent of the Era of Individualization. The New England Journal of Medicine 347(21):1705-1708,2002 |
| Hiroshi Yagi, Masakazu Ueda, Hiromitsu Jinnno, Koichi Aiura, Shuji Mikami, Hiroko Tada, Masaharu Seno, Hidenori Yamada and Masaki Kitajima: Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. Cancer Science 97(12):1315-1320, 2006 |
| Hiroya Takeuchi, MD, Hirohumi Fujii, MD, Nobutoshi Ando, MD, Soji Ozawa, MD, Yoshiro Saikawa, MD, Koichi Suda, MD, Takashi Oyama, MD, Makio Mukai, MD, Tadaki Nakahara, MD, Atsushi Kubo, MD, Masaki Kitajima, MD, and Yuko Kitagawa, MD: Validation Study of Radio-Guided Sentinel Lymph Node Navigation in Dsophageal Cancer: Annals of Surgery/Volume 249, p757-762: Number 5, May 2009 |
|
| ○ |
| 高橋 利忠 |
健康科学総合センター 名誉センター長 |
| 腫瘍免疫学 |
Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen.
Tsujimura, K., Obata, Y., Takahashi, T.
Cancer Sci.2004; 95: 469-474. |
Kawase,T.,Akatsuka,Y.,Torikai,H.,Morishima,S.,Oka,A.,Tsujimura,A.,
Miyazaki,M.,Tsujumura,K.,Miyamura,K.,Ogawa,S.,Inoko,H.,
Morishima,Y., Kodera,y., Kuzushima,K.., Takahashi,T.
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.
Blood. 2007; 110: 1055-1063. |
A Minor histocompatibility antigen as targets for immunotherapy utilizing allogeneic immune reactions.
Akatuka, Y., Morishima, Y., Kuzushima, K., Kodera, Y., Takahashi, T
Cancer Sci. 2009;78:1139-1146 |
|
| |
| 中西 洋一 |
九州大学大学院医学研究院 教授 |
| 臨床腫瘍学・呼吸器内科学・臨床試験 |
IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population.
Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y.
J Thorac Oncol 5:299-304,2010 |
Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.
Zhang H, Takayama K, Zhang L, Uchino J, Harada A, Harada T, Hisasue J, Nakagaki N, Zhou C, Nakanishi Y
Cancer Gene Ther 16:415-422,2009 |
A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer.
N Ebi, H Semba, S Tokunaga, K Takayama, H Wataya, T Kuraki, H Yamamoto, S Akamine, I Okamoto, Y Nakanishi. (Lung Oncology Group in Kyushu Japan)
J Thorac Oncol 10:1166-1171, 2008 |
|
| |
| 野田 哲生 |
公益財団法人がん研究会がん研究所 所長 |
|
| |
| 福岡 正博 |
和泉市立病院がんセンター センター長 |
| 臨床腫瘍学 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. J Clin Oncol 29(21): 2866-74, 2011. |
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. N Engl J Med. 361(10): 947-57, 2009. |
| Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst.83(12): 855-61, 1991. |
|
| |
| 門田 守人 |
公益財団法人がん研究会有明病院 院長 |
| 消化器外科 |
| 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. Hepatol Res. 2012; 42(2):150-65. |
| Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, Miyata H, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Matsuura N, Matsubara K, Monden M, Mori M, Doki Y. Int J Oncol. 2010; 37(5):1113-20. |
| Exploration of potential genomic portraits associated with intrahepatic recurrence in human hepatocellular carcinoma. Kittaka N, Takemasa I, Seno S, Takeda Y, Kobayashi S, Marubashi S, Dono K, Umeshita K, Nagano H, Matsuda H, Monden M, Mori M, Doki Y. Ann Surg Oncol. 2010; 17(12): 3145-54. |
|
